US Supreme Court Declines Review Of False Claims Act, PCSK9, Hep C Patents

Gilead disputed Campie FCA decision, Amgen challenged Repatha ruling, and Merck challenged "unclean hands" defense against damages. Patent and Trademark Office wants court to determine if its attorneys' fees should be covered by patent applicants challenging its decisions.

US Supreme Court building with 2nd statue on right

Heeding the advice of the Solicitor General, the US Supreme Court denied Gilead Sciences Inc.'s petition asking it to specify how False Claims Act cases should be resolved when the government knows about a company's alleged misrepresentations about a product but continues to pay for it.

In its Jan. 7 orders, the court denied three pharma-related petitions for certiorari. The other petitions were filed by

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet